MAPS Responds to Report of Progress for MDMA-assisted therapy for PTSD with FDA
MAPS responded to a report stating that Resilient Pharmaceuticals resubmitted its New Drug Application for MDMA-assisted therapy for PTSD to the FDA. This development signifies ongoing progress in the regulatory review of MDMA-assisted therapy.
By Zane Bader · Published August 13, 2026
Sourced from maps.org, published August 10, 2026. Cite the original publication, not this page, for the reporting itself.
MAPS responded to a report stating that Resilient Pharmaceuticals resubmitted its New Drug Application for MDMA-assisted therapy for PTSD to the FDA. This development signifies ongoing progress in the regulatory review of MDMA-assisted therapy.